The FDA’s September 2026 warning letter to Empower Pharmacy cites compounded semaglutide and tirzepatide prescriptions with missing or repeated “significant difference” determinations and questions the individualized nature of those determinations.
FDA Cites Section 503A Concerns With Compounded GLP-1 Prescriptions
On September 18, 2026, the FDA issued a warning letter to Houston-based Empower Pharmacy after investigators found compounded semaglutide and tirzepatide products that the agency stated failed to meet Section 503A conditions, including requirements involving patient-specific “significant difference” determinations. The FDA also cited adulterated and misbranded drug products, providing federal-level compliance context for Med Spas and wellness clinics offering GLP-1 and weight-loss medication services.
FDA Inspection Identifies Section 503A Concerns at Empower Pharmacy in Texas
The warning letter follows a November 2025 FDA inspection of Empower Pharmacy in Houston. Investigators found evidence indicating that compounded products failed to meet conditions under Section 503A of the Federal Food, Drug, and Cosmetic Act.
The FDA identified findings involving compounded GLP-1 products:
- Semaglutide and tirzepatide: Semaglutide/cyanocobalamin and two tirzepatide/niacinamide formulations appeared to be essentially copies of FDA-approved products.
- Production volume: Records documented recurring orders for all three formulations from July through October 2025, which the FDA cited as evidence that the products were compounded regularly or in inordinate amounts.
The FDA stated that the volume suggested differences between the compounded and FDA-approved products were “pretextual.” Section 503A generally restricts compounding drugs that are essentially copies of commercially available products unless a prescriber determines that a change made for an identified individual patient produces a “significant difference” for that patient.
FDA Reviews “Significant Difference” Determinations
The FDA reviewed whether those patient-specific determinations appeared in orders and prescriptions collected during the inspection.
The agency identified several findings:
- Missing determinations: Some prescriptions contained no prescriber determination of a significant difference.
- Repeated language: Other determinations appeared verbatim across multiple records, which the FDA stated suggested they may have been pre-generated for prescriber selection.
- Pre-selected statements: The FDA cited technology platforms offering pre-selected statements as a method that could call the individualized nature of those determinations into question.
The agency considered the prescribing records and production volume in concluding that the products did not meet Section 503A conditions.
Warning Letter Also Cites Adulterated and Misbranded Products
The FDA separately cited insanitary conditions and current good manufacturing practice, or CGMP, violations involving sterile drug production.
Additional findings included:
- Sterile production: Inadequate smoke studies and media fills used to evaluate aseptic processing.
- Drug status: The FDA stated that affected products were adulterated and that ineligible compounded products were also misbranded for lacking adequate directions for use.
CGMP requirements establish manufacturing and quality controls for drug products. The FDA directed Empower to respond within 15 working days with corrective steps and supporting documentation.
Source: FDA Warning Letter
According to the FDA’s September 18, 2026 warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, the findings followed an agency inspection of the company’s Houston facility in November 2025. The FDA warning letter details the agency’s Section 503A findings, adulteration and misbranding findings, prescribing concerns, and CGMP findings.
Compliance Context on Compounded Drugs, Significant Difference Exceptions, and FDA GLP-1 Oversight
In this case, the FDA’s findings extend beyond pharmacy production practices to the orders and prescriptions supporting compounded GLP-1 products. The warning letter details the “significant difference” determinations in prescription documentation the agency reviewed.
The findings also follow the FDA’s determination that shortages of tirzepatide and semaglutide injection products had resolved in December 2024 and February 2025, respectively. Section 503A generally restricts regular or inordinate compounding of drugs that duplicate commercially available products, while allowing an exception when a prescriber determines that a change produces a significant difference for a specific patient.
Key compliance points in the Empower Pharmacy case include:
- Patient-specific determinations
- Prescription documentation
- Compounded drug restrictions
- Sterile production quality requirements
The warning letter adds to recent federal activity involving GLP-1 and peptide products, including FDA warning letters involving peptide and GLP-1 products and FDA action involving telehealth GLP-1 marketing and prescribing practices. These actions have addressed compounded and unapproved drug products, product marketing, prescription documentation, and prescriber responsibilities. For Med Spas and wellness clinics offering GLP-1 and weight-loss services, federal drug requirements may apply alongside state laws and professional licensing requirements governing prescribing, drug administration, and clinical practice.
The FDA reviewed whether “significant difference” determinations in prescription documentation supported the compounding of GLP-1 products.
Practical and Educational Implications for Med Spas and Weight-Loss Clinics
- Distinguish between FDA-approved and compounded GLP-1 products.
- Review Section 503A requirements involving patient-specific “significant difference” determinations where applicable.
- Differentiate individualized prescriber determinations from repeated or pre-generated prescription language.
- Consider pharmacy sourcing and product status when evaluating GLP-1 treatment options.
- Recognize sterile production and drug quality requirements as separate from the conditions for compounding under Section 503A.
- Follow FDA Section 503A and compounded drug updates affecting GLP-1 products and prescribing practices.
What to Watch Next
Empower Pharmacy was given 15 working days to respond to the warning letter with corrective actions and supporting documentation. Additional FDA action may provide further information on the company’s response and the status of the findings involving compounded GLP-1 products and “significant difference” determinations.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “FDA Bldg 31 – Great Room” by The U.S. Food and Drug Administration, via Wikimedia Commons, licensed under Public Domain.
